In two small studies, peanut allergies improved
in children who took low doses of peanut allergens that gradually increased
over time.
Exposing a person to low doses of a known
allergen, a technique called immunotherapy, is not a new concept. The goal of
immunotherapy is to desensitize the patient so that the body builds up a
tolerance to the allergen. For example, immunotherapy has been used to treat
seasonal allergies and vaccine allergies.
Peanut allergy is the leading cause of severe
allergic reactions in children and adults in the
In the first study, 15 children received very
small, gradually increasing doses of peanut powder, while eight children
received a placebo for one year. By the end of the study, children in the
peanut group were able to tolerate an average of 15 peanuts before developing
allergic responses.
The second study included 12 children who had
been treated with peanut powder beginning at 32 months of age and ending at
five years of age. One month after discontinuing immunotherapy, the children
were given peanuts. Nine of the participants were able to tolerate the peanuts
and are now able to include them in their diets.
The findings, which were presented at the
annual meeting of the American Academy of Allergy, Asthma & Immunology, support earlier studies, which suggested that
immunotherapy may help treat peanut and milk allergies.
Because food allergies can be potentially life
threatening, immunotherapy is not recommended for general use. Until the safety
of this treatment is tested in a larger population, people with allergies
should avoid foods that trigger their allergies.
For more information about food allergies,
please visit Natural Standard's Medical
Conditions database.